Findings presented at the 2021 American College of Rheumatology Annual Meeting showed that patients with concomitant psoriasis and psoriatic arthritis (PsA) reported greater incidence of obesity, hypertension, and diabetes, as well as a higher likelihood of work inability than those with only psoriasis.
According to findings presented at the 2021 American College of Rheumatology (ACR) Annual Meeting, concomitant diagnosis of psoriasis and psoriatic arthritis (PsA) may lead to greater comorbidity burden and work impairment than psoriasis alone.
Affecting more than 7.5 million US adults, psoriasis has been linked with incidence of PsA development. Prior research has suggested approximately one-third of patients with psoriasis will develop PsA during the course of their disease, which may pose added health risks and greater health care utilization concerns.
Seeking to evaluate baseline characteristics and comorbidities in patients with psoriasis with and without a PsA diagnosis, researchers conducted a retrospective observational study using data of the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
“As patient cohorts included in randomized clinical trials are not necessarily representative of the real world, registry data can complement information gained on patient characteristics and disease outcomes,” they explained.
In the study, patients were stratified and compared on whether they had psoriasis alone or concomitant psoriasis and PsA, as well as whether they used ustekinumab as their biologic treatment or received conventional systemic antipsoriatic medication:
Participants were evaluated at baseline for several characteristics, including body mass index, smoking, employment status, and comorbidities such as diabetes, hypertension, myocardial infarction, and depression.
Compared with patients with just psoriasis, those with concomitant psoriasis and PsA were found to be 73% less likely to report ability to work when administered ustekinumab treatment (odds ratio [OR], 0.27; 95% CI, 0.21-0.35) and 51% less likely when given conventional systemic (OR, 0.49; 95% CI, 0.37-0.65).
Moreover, patients with concomitant psoriasis and PsA across both treatment types were found to be at significantly greater risk of reporting diabetes (ustekinumab: OR, 1.45; 95% CI, 1.10-1.89; conventional systemic treatment: OR, 1.51; 95% CI, 1.11-2.04), obesity (ustekinumab: OR, 1.34; 95% CI, 1.11-1.62; conventional systemic treatment: OR, 1.21; 95% CI, 1.01-1.46), and hypertension (ustekinumab: OR, 1.54; 95% CI, 1.26-1.87; conventional systemic treatment: OR, 1.30; 95% CI, 1.03-1.62) compared with those with only psoriasis.
Patients with psoriasis and comorbid PsA receiving ustekinumab were also more likely to have a diagnosis of depression than those receiving conventional systemic treatment in comparisons with those with only psoriasis (ustekinumab: OR, 1.54; 95% CI, 1.25-1.88; conventional systemic treatment: OR, 1.14; 95% CI, 0.91-1.42)
“These results potentially indicate a higher inflammatory and quality-of-life burden in patients with psoriasis and comorbid PsA, highlighting the need for adequate patient assessment and follow-up to ensure a best possible holistic patient management approach,” concluded the study authors.
Reference
Tillett W, Ogdie A, Gorecki P, Passey A. Differences in real-world patient characteristics of 8921 patients with psoriasis with and without comorbid psoriatic arthritis using the UK BADBIR database. Presented at: ACR Convergence 2021; Virtual. Abstract 1354. https://bit.ly/3DAnH9P
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Panel Addresses Minority Physician Shortage, Maternal Health at Senate Committee Hearing
May 15th 2024The senate hearing held by the US Senate Committee on Health, Education, Labor, and Pensions, led by Sen. Bernie Sanders (I, Vermont), chairman of the committee, and ranking member Sen. Bill Cassidy, MD, (R, Louisiana), addressed the critical issue of physician and health care worker shortages, as well as the maternal health crisis, in the US.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
A new study highlights significant disparity in reimbursement rates across states between hospitals and Medicare; the first patient to receive a genetically modified pig kidney has died; research examines outcomes of over 500 patients receiving medication abortion pills by mail.
Read More